Med24
peptide-development 21. 9. 2026 • 2 min read • The Journal of clinical endocrinology and metabolism

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling

Context In a 28-week clinical trial of patients with type 2 diabetes (T2D), tirzepatide 15 mg (a dual GIP/GLP-1 receptor agonist) and semaglutide 1 mg (a GLP-1 receptor agonist) both improved fasting glucose, with tirzepatide showing superior efficacy. The longitudinal metabolic mechanisms underlying this difference...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A study investigated the longitudinal metabolic effects of Tirzepatide and Semaglutide in patients with type 2 diabetes (T2D) following a 28-week clinical trial.

Mechanistic Analysis and Key Findings

The research utilized a mechanistic longitudinal model incorporating fasting glucose, fasting insulin, insulin sensitivity, and beta-cell function to analyze the data. The model allowed for quantification of hepatic glucose production (HGP) and the isolation of drug effects on HGP. The study found that both Tirzepatide 15 mg and Semaglutide 1 mg improved fasting glucose. Tirzepatide demonstrated superior efficacy in this comparison.

Sponsored content

Longitudinal Metabolic Changes

The model revealed an initial increase in beta-cell function, followed by a decline in insulin sensitivity, representing a reversal of the typical progression of T2D. The superior fasting glucose control observed with Tirzepatide was primarily attributed to greater insulin-independent suppression of HGP. Patients exhibiting low responses to treatment displayed deficient HGP suppression. Simulations suggested that enhancing HGP suppression could improve fasting glucose without inducing beta-cell stress associated with sustained hypersecretion. Simulated weight loss accelerated early glycemic improvement, but did not further reduce long-term fasting glucose levels. The findings indicate that greater suppression of hepatic glucose production is associated with greater efficacy in improving fasting glucose. Therapeutic strategies focused on suppressing HGP may offer metabolic benefits beyond direct enhancement of beta-cell function or additional weight loss.

Original Scientific Source
The Journal of clinical endocrinology and metabolism
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement